Effect of Gefitinib Combined with Chemotherapy in Patients with Advanced NSCLC: A Retrospective Cohort Study

Lili Dai,1,* Wei Wang,2,* Wenli Li,3 Ya Wu,3 Kaixin Qu2 1Department of Geriatrics, Funan County People’s Hospital, Fuyang, People’s Republic of China; 2Department of Respiratory Medicine, Funan County People’s Hospital, Fuyang, People’s Republic of China; 3Department of Respiratory M...

Full description

Bibliographic Details
Main Authors: Dai L, Wang W, Li W, Wu Y, Qu K
Format: Article
Language:English
Published: Dove Medical Press 2022-01-01
Series:International Journal of General Medicine
Subjects:
Online Access:https://www.dovepress.com/effect-of-gefitinib-combined-with-chemotherapy-in-patients-with-advanc-peer-reviewed-fulltext-article-IJGM
_version_ 1819008277583757312
author Dai L
Wang W
Li W
Wu Y
Qu K
author_facet Dai L
Wang W
Li W
Wu Y
Qu K
author_sort Dai L
collection DOAJ
description Lili Dai,1,&ast; Wei Wang,2,&ast; Wenli Li,3 Ya Wu,3 Kaixin Qu2 1Department of Geriatrics, Funan County People’s Hospital, Fuyang, People’s Republic of China; 2Department of Respiratory Medicine, Funan County People’s Hospital, Fuyang, People’s Republic of China; 3Department of Respiratory Medicine, Fuyang Hospital, Anhui Medical University, Fuyang, People’s Republic of China&ast;These authors contributed equally to this workCorrespondence: Kaixin QuDepartment of Respiratory Medicine, Funan County People’s Hospital, No. 18, Santa Road, Funan County, Fuyang City, 236300, People’s Republic of ChinaTel +86 17755806231Email qukaixin19770418@163.comBackground: There are currently no methods for the treatment of reversible drug-resistant EGFR-TKI lung cancer in the clinical setting, and thus, the patients finally return to the currently used drugs. This study aimed to compare the efficacy of chemotherapy alone and gefitinib combined with chemotherapy in the treatment of non-small cell lung cancer (NSCLC) patients in advanced stage with the mutation of epidermal growth factor receptor (EGFR).Methods: A retrospective analysis was carried out on 120 patients with advanced EGFRm+ NSCLC who were divided into the control group (CG, received chemotherapy alone) or the observation group (OG, received chemotherapy and gefitinib) according to the treatment methods.Results: Comparison of the objective response rates (ORRs) showed no statistical significant difference between OG (36.92%) and CG (29.09%, P > 0.05), whereas in OG, disease control rate (DCR) was significantly increased in comparison with CG (P < 0.05). The medians of progression-free survival (PFS) and overall survival (OS) in OG were 8.0 months and 24.0 months, respectively, which were longer than 5.0 months and 18.0 months in CG (P = 0.031). The univariate analysis revealed that clinical stage of tumor (HR = 1.590, 95% CI: 1.097– 2.343) was the prognostic factor for advanced lung cancer. Multi-factor Cox regression analysis revealed that clinical analysis was an independent prognostic factor (HR = 1.701, 95% CI: 1.099– 2.632).Conclusion: In PFS patients, the OS rate was significantly improved, which was worth for clinical use.Keywords: advanced non-small cell lung cancer, NSCLC, anti-vascular therapy, prognosis
first_indexed 2024-12-21T00:37:55Z
format Article
id doaj.art-b87f8993656f47509b064ee6625322c0
institution Directory Open Access Journal
issn 1178-7074
language English
last_indexed 2024-12-21T00:37:55Z
publishDate 2022-01-01
publisher Dove Medical Press
record_format Article
series International Journal of General Medicine
spelling doaj.art-b87f8993656f47509b064ee6625322c02022-12-21T19:21:45ZengDove Medical PressInternational Journal of General Medicine1178-70742022-01-01Volume 1563764472324Effect of Gefitinib Combined with Chemotherapy in Patients with Advanced NSCLC: A Retrospective Cohort StudyDai LWang WLi WWu YQu KLili Dai,1,&ast; Wei Wang,2,&ast; Wenli Li,3 Ya Wu,3 Kaixin Qu2 1Department of Geriatrics, Funan County People’s Hospital, Fuyang, People’s Republic of China; 2Department of Respiratory Medicine, Funan County People’s Hospital, Fuyang, People’s Republic of China; 3Department of Respiratory Medicine, Fuyang Hospital, Anhui Medical University, Fuyang, People’s Republic of China&ast;These authors contributed equally to this workCorrespondence: Kaixin QuDepartment of Respiratory Medicine, Funan County People’s Hospital, No. 18, Santa Road, Funan County, Fuyang City, 236300, People’s Republic of ChinaTel +86 17755806231Email qukaixin19770418@163.comBackground: There are currently no methods for the treatment of reversible drug-resistant EGFR-TKI lung cancer in the clinical setting, and thus, the patients finally return to the currently used drugs. This study aimed to compare the efficacy of chemotherapy alone and gefitinib combined with chemotherapy in the treatment of non-small cell lung cancer (NSCLC) patients in advanced stage with the mutation of epidermal growth factor receptor (EGFR).Methods: A retrospective analysis was carried out on 120 patients with advanced EGFRm+ NSCLC who were divided into the control group (CG, received chemotherapy alone) or the observation group (OG, received chemotherapy and gefitinib) according to the treatment methods.Results: Comparison of the objective response rates (ORRs) showed no statistical significant difference between OG (36.92%) and CG (29.09%, P > 0.05), whereas in OG, disease control rate (DCR) was significantly increased in comparison with CG (P < 0.05). The medians of progression-free survival (PFS) and overall survival (OS) in OG were 8.0 months and 24.0 months, respectively, which were longer than 5.0 months and 18.0 months in CG (P = 0.031). The univariate analysis revealed that clinical stage of tumor (HR = 1.590, 95% CI: 1.097– 2.343) was the prognostic factor for advanced lung cancer. Multi-factor Cox regression analysis revealed that clinical analysis was an independent prognostic factor (HR = 1.701, 95% CI: 1.099– 2.632).Conclusion: In PFS patients, the OS rate was significantly improved, which was worth for clinical use.Keywords: advanced non-small cell lung cancer, NSCLC, anti-vascular therapy, prognosishttps://www.dovepress.com/effect-of-gefitinib-combined-with-chemotherapy-in-patients-with-advanc-peer-reviewed-fulltext-article-IJGMadvanced non-small cell lung cancer (nsclc)anti-vascular therapyprognosis
spellingShingle Dai L
Wang W
Li W
Wu Y
Qu K
Effect of Gefitinib Combined with Chemotherapy in Patients with Advanced NSCLC: A Retrospective Cohort Study
International Journal of General Medicine
advanced non-small cell lung cancer (nsclc)
anti-vascular therapy
prognosis
title Effect of Gefitinib Combined with Chemotherapy in Patients with Advanced NSCLC: A Retrospective Cohort Study
title_full Effect of Gefitinib Combined with Chemotherapy in Patients with Advanced NSCLC: A Retrospective Cohort Study
title_fullStr Effect of Gefitinib Combined with Chemotherapy in Patients with Advanced NSCLC: A Retrospective Cohort Study
title_full_unstemmed Effect of Gefitinib Combined with Chemotherapy in Patients with Advanced NSCLC: A Retrospective Cohort Study
title_short Effect of Gefitinib Combined with Chemotherapy in Patients with Advanced NSCLC: A Retrospective Cohort Study
title_sort effect of gefitinib combined with chemotherapy in patients with advanced nsclc a retrospective cohort study
topic advanced non-small cell lung cancer (nsclc)
anti-vascular therapy
prognosis
url https://www.dovepress.com/effect-of-gefitinib-combined-with-chemotherapy-in-patients-with-advanc-peer-reviewed-fulltext-article-IJGM
work_keys_str_mv AT dail effectofgefitinibcombinedwithchemotherapyinpatientswithadvancednsclcaretrospectivecohortstudy
AT wangw effectofgefitinibcombinedwithchemotherapyinpatientswithadvancednsclcaretrospectivecohortstudy
AT liw effectofgefitinibcombinedwithchemotherapyinpatientswithadvancednsclcaretrospectivecohortstudy
AT wuy effectofgefitinibcombinedwithchemotherapyinpatientswithadvancednsclcaretrospectivecohortstudy
AT quk effectofgefitinibcombinedwithchemotherapyinpatientswithadvancednsclcaretrospectivecohortstudy